bubble image


Strategic Investor Support

Arcutis Biotherapeutics’ combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector, including: Bain Capital Life Sciences, BlackRock, Frazier Healthcare Partners, Goldman Sachs, HBM Healthcare Investments, Hillhouse Capital Group, Omega Funds, OrbiMed, Pivotal BioVentures, RA Capital Management, Rainbow Group Capital Management and Vivo Capital. Arcutis has successfully completed Series A, Series B and Series C financings, the proceeds of which are funding its clinical development programs and corporate operations.  Since its founding in 2016, Arcutis has raised approximately $160 million.